Skip to main content
FAIR Healthdata
About Sciensano |Log in
  • Datasets
  • How-it-works
  • Sources
  • FAIR Principles
  • Roadmap
  • Add your project
  • Home
  • Home
  • Datasets
  • Datasets

Source

  • EudraCT (31744) Apply EudraCT filter
  • FODPH - Hospitals (399) Apply FODPH - Hospitals filter
  • Metadata (254) Apply Metadata filter

Format

  • json (32397) Apply json filter

License

  • Creative Commons Attribution (32397) Apply Creative Commons Attribution filter
21 - 25 of 32397 results
Search TipsAdvanced Search

Estudio fase 2a2b de BMS-650032 en combinacin con Peginterferon ALFA-2a PEGASYS y Ribavirina COPEGUS en pacientes naive con Hepatitis C crnica con Genotipos 1 y 4 Protocolo Revisado 01 que incorpora la Enmienda 03 v10 de fecha 15-Feb-2010 A Phase 2a2b study of BMS-650032 in Combination With Peginterferon Alfa-2a Pegasys and Ribavirin Copegus in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection Revised Protocol 01 incorporating Protocol Amendment 03 v10 dated 15-Feb-2010

json

Superioridad de insulina glargina Lantus frente a NPH: Tratar hasta alcanzar la Normoglucemia Comparacin del efecto de insulina glargina vs insulina NPH en pacientes con diabetes mellitus de tipo 2 no tratados previamente con insulina que reciben al menos un antidiabtico oral y no estn bien controlados

json

A phase III randomised double-blind placebo-controlled parallel group efficacy and safety study of BI 10773 10 mg 25 mg administered orally once daily over 24 weeks in patients with type 2 diabetes with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea

A phase III randomised double-blind placebo-controlled parallel group efficacy and safety study of BI 10773 10 mg 25 mg administered orally once daily over 24 weeks in patients with type 2 diabetes with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea

json

Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations

Klinisk prvning med kombinationsbehandling av kemoterapi och antikroppar fr behandling av patienter med gallgngscancer som inte kan opereras

json

A 14-Month Open-Label Extension Phase of the Double-Blind Placebo-Controlled Dose-Escalation Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures revised per Amendments 02 and 03

json
  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »
  • Twitter
  • Linkedin
  • Data Licences
  • Terms of service
  • FAQ
  • HEALTHDATA.be
  • Contact